Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis

Chen, Bin; Wang, Yonghong; Qian, Jinqin; Wu, Dongbo; Chen, En‐Qiang; Tang, Hong

doi:10.1097/meg.0000000000001156

Cited by 18 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite rash and fever (37-38 • C) in several cases that resolved without additional treatment (24), no significant adverse effects were reported in most clinical trials. A series of meta-analysis results also proved the therapeutic efficacy and safety of MSCs from different sources in patients with ALF, liver cirrhosis and end-stage liver disease associated with HBV and HCV (22,(140)(141)(142).…”

Section: Safety Issues Associated With Msc Transplantationmentioning

confidence: 87%

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

et al. 2021

View full text Add to dashboard Cite

Mesenchymal stem cell (MSC) transplantation is a novel treatment for liver diseases due to the roles of MSCs in regeneration, fibrosis inhibition and immune regulation. However, the mechanisms are still not completely understood. Despite the significant efficacy of MSC therapy in animal models and preliminary clinical trials, issues remain. The efficacy and safety of MSC-based therapy in the treatment of liver diseases remains a challenging issue that requires more investigation. This article reviews recent studies on the mechanisms of MSCs in liver diseases and the associated challenges and suggests potential future applications.

show abstract

Section: Safety Issues Associated With Msc Transplantationmentioning

confidence: 87%

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Another study on MSC transplantation for the treatment of ACLF patients also achieved similar results, in which the treatment increased the 24-wk survival rate, improved liver function, and decreased the incidence of severe infections[11]. Moreover, we recently conducted a systematic review and meta-analysis of MSC transplantation in ACLF patients, which showed that the treatment significantly reduced mortality rates, without increasing the incidence of severe complications[13]. There were also no differences in the incidence of severe complications ( e.g ., encephalopathy, hepatorenal syndrome, gastrointestinal bleeding) between the standard medical treatment and the MSC treatment group in ACLF patients[5].…”

Section: Treatment Of End-stage Liver Disease Via Stem Cell Transplanmentioning

confidence: 79%

Stem cell transplantation for the treatment of end-stage liver disease

Chen

Tang

2018

WJH

Self Cite

View full text Add to dashboard Cite

The past two decades have witnessed an explosion of research and clinical application of stem cells, transforming the field of regenerative medicine. Stem cell transplantation has already been performed to treat patients with cancer, liver diseases, and various types of chronic diseases. Indeed, stem cell-based therapies are effective in many diseases, and provide novel insights into the treatment of end-stage liver disease. Several clinical trials have indicated the efficacy profiles of stem cell transplantation in patients with end-stage liver disease, including liver cirrhosis, liver failure, and liver tumors. Animal models of acute liver failure have also provided important insights into the safety, mechanisms, and efficacy of stem cell therapies. Nevertheless, excitement due to this promising field must be tempered with careful and calculated research. In particular, studies on the quality, safety, and efficacy of stem cell transplantation are needed to ensure that qualified products are tested in well-designed clinical trials and approved by governments. Therefore, further investigations are required to effectively balance the safety with the innovation of stem cell transplantation research toward the effective treatment of end-stage liver disease.

show abstract

“…In the era of regenerative medicine, MSCs have emerged as a novel approach for HBV-ACLF treatment due to their ability to home to damaged tissues, hypoimmunogenicity that allows allogenic transplantation, anti-inflammatory effects and their differentiation capacity into functional hepatocyte-like cells [36,37]. An study by Peng and colleagues investigated the therapeutic effects of single transfusion of culture expanded autologous Bone marrow (BM)-MSCs in HBV-associated liver failure patients [38].…”

Section: Mscs and Hepatitis B Virus (Hbv)mentioning

confidence: 99%

Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy

Sleem

Saleh

2020

Current Research in Translational Medicine

View full text Add to dashboard Cite

The relative ease of isolation of mesenchymal stem cells (MSCs) from different tissues coupled with their culture expansion in vitro and their differentiation capacity to mesodermal, endodermal and ectodermal lineages have made these cells attractive for a large number of therapeutic applications. In recent years, there has been remarkable progress in the utilization of MSCs in diverse clinical indications both in animal models and human clinical trials. However, the potential of MSCs to control or treat viral diseases is still in its infancy. In this study, we report quantitative data on the MSC-based clinical trials over the last ten years as they appear on the online database of clinical research studies from US National Institutes of Health. In particular, we provide comprehensive review of either completed or ongoing clinical trials using MSCs for virus-associated diseases focusing on HIV, hepatitis B virus and COVID-19 virus.

show abstract

Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis

Abstract: Our pooled results suggested that MSC treatment could significantly reduce the mortality rate, without increasing the incidence of severe complications.

Cited by 18 publications

References 15 publications

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

Stem cell transplantation for the treatment of end-stage liver disease

Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy

Contact Info

Product

Resources

About